Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Glepaglutide is a peptide agonist of the glucagon-like peptide 2 receptor (GLP-2R).1 It selectively induces cAMP accumulation in HEK293 cells expressing GLP-2R over those expressing GLP-1R (EC50s = 0.24 and 8.7 nM, respectively, for the human receptors). Glepaglutide (10 mg/kg per day for 26 weeks) increases mucosal hyperplasia thickness in the duodenum, jejunum, and ileum, as well as increases small intestinal wet weight and length, an effect that lasts six weeks post-administration, in rats.2 It also increases small intestinal mass and length, as well as reduces ileal levels of α-1-acid glycoprotein (AGP 1) and myeloperoxidase (MPO), in a rat model of inflammatory bowel disease (IBD) induced by indomethacin (Item No. 70270) when administered at a dose of 400 nmol/kg twice per day.3
WARNING This product is not for human or veterinary use.
1. Pharmacological characterization of apraglutide, a novel long-
2. Short-
3. Glepaglutide, a novel glucagon-